Back to News
Market Impact: 0.35

Evercore ISI reiterates Microsoft stock rating on Azure growth potential By Investing.com

EVRMSFTBCSBRKRTXGSMCIAPP
Artificial IntelligenceTechnology & InnovationCorporate EarningsAnalyst InsightsAnalyst EstimatesProduct LaunchesCapital Returns (Dividends / Buybacks)Company Fundamentals
Evercore ISI reiterates Microsoft stock rating on Azure growth potential By Investing.com

Microsoft reported total revenue growth of 15% (constant currency) in the quarter with Azure up 38%; Evercore ISI reiterated an Outperform and $580 PT (Barclays $600) but flagged capacity constraints that push Azure acceleration into H2 CY2026, helping explain a 25% share decline over six months. Evercore expects Azure could accelerate above 40% in H2 CY2026 and says Microsoft 365 E7 could add ~2.4–2.5% to FY2028 Microsoft 365 Commercial Cloud revenue (FY2028 est. $105.1bn); the stock trades at 18.5x GAAP EPS. Microsoft also announced a $0.91 quarterly dividend payable June 11, 2026 and introduced Copilot Wave 3 and the E7 SKU, reinforcing its AI-driven enterprise strategy.

Analysis

Winners will be the parts of the stack that relieve hyperscaler GPU bottlenecks: OEMs that enable private/hybrid inference (server vendors, system integrators, memory and power-supply suppliers) and software layers that reduce model GPU-hours (distillation, sparsity tooling). Niche instrument and spatialomics vendors face a second-order hit as enterprise AI spending reallocates to compute and platform consolidation; expect selective partnership and data-access deals to determine midcap winners versus losers. Near-term price action will be driven by capacity cadence and enterprise procurement windows — days-weeks moves will be sentiment-led around supply commentary, while durable revenue inflection requires multi-quarter enterprise rollouts and procurement renewals (6–18 months). Tail risks that would materially reverse a constructive view are a sudden broad-based GPU supply shock, model-efficiency advances that materially cut cloud GPU demand, or regulatory constraints on model/data usage; constructive triggers are clearer capacity guidance, material E7-style bundle upsell metrics, or large deal disclosures. Actionable trade angles bifurcate between infrastructure capture and thematic reallocation away from niche bio tools. One can play the infrastructure squeeze with concentrated convexity in system vendors and software that monetizes private inference, while expressing skepticism on specialized spatialomics names that lack a clear path to capture AI-infra dollars. The consensus is anchored to near-term capacity and capex risks, overlooking how product bundling and workflow ownership can create durable wallet share and margin upside once enterprises cross implementation thresholds. That suggests current skepticism may be at least partially priced in; the clearest evidence that the market is wrong will be adoption metrics (seat counts, bundle attach rates) rather than quarterly headline growth alone.